A Cross-Sectional Evaluation of the Effect of Risperidone and Selective Serotonin Reuptake Inhibitors on Bone Mineral Density in Boys

被引:58
作者
Calarge, Chadi A. [1 ]
Zimmerman, Bridget [3 ]
Xie, Diqiong [3 ]
Kuperman, Samuel [1 ]
Schlechte, Janet A. [2 ]
机构
[1] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA
[2] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA 52242 USA
基金
美国国家卫生研究院;
关键词
KAPPA-B LIGAND/OSTEOPROTEGERIN; PROLACTIN LEVELS; INDUCED HYPERPROLACTINEMIA; RECEPTOR ACTIVATOR; CHILDREN; ADOLESCENTS; WOMEN; SCHIZOPHRENIA; FLUOXETINE; EXPRESSION;
D O I
10.4088/JCP.08m04595gre
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents. Method: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this crosssectional study through child psychiatry outpatient clinics between November 2005 and June 2007. Anthropometric measurements and laboratory testing were conducted. The clinical diagnoses were based on chart review, and developmental and treatment history was obtained from the medical record. Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry. Results: Hyperprolactinemia was present in 49% of 83 boys (n =41) treated with risperidone for a mean of 2.9 years. Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia. As expected, bone mineral content and BMD increased with sexual maturity. After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P<.03). Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P=.03) and BMD z score at the lumbar spine (P<.05). These findings became more marked when the analysis was restricted to non-Hispanic white patients. Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia. Conclusions: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents. Future 'research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues. J Clin Psychiatry 2010;71(3):338-347 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
引用
收藏
页码:338 / 347
页数:10
相关论文
共 60 条
[11]   Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake [J].
Bliziotes, MM ;
Eshleman, AJ ;
Zhang, XW ;
Wiren, KM .
BONE, 2001, 29 (05) :477-486
[12]   Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling [J].
Bonnet, N. ;
Bernard, P. ;
Beaupied, H. ;
Bizot, J. C. ;
Trovero, F. ;
Courteix, D. ;
Benhamou, C. L. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 221 (01) :111-118
[13]   Biology of RANK, RANKL, and osteoprotegerin [J].
Boyce, Brendan F. ;
Xing, Lianping .
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (Suppl 1)
[14]   Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents [J].
Calarge, Chadi A. ;
Acion, Laura ;
Kuperman, Samuel ;
Tansey, Michael ;
Schlechte, Janet A. .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (02) :101-109
[15]   Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents [J].
Calarge, Chadi A. ;
Ellingrod, Vicki L. ;
Acion, Laura ;
Miller, Del D. ;
Moline, Jessica ;
Tansey, Michael J. ;
Schlechte, Janet A. .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (05) :373-382
[16]   Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization [J].
Colao, A ;
Di Somma, C ;
Loche, S ;
Di Sarno, A ;
Klain, M ;
Pivonello, R ;
Pietrosante, M ;
Salvatore, M ;
Lombardi, G .
CLINICAL ENDOCRINOLOGY, 2000, 52 (03) :319-327
[17]   Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents [J].
Correll, Christoph U. ;
Carlson, Harold E. .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (07) :771-791
[18]   The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia [J].
David, SR ;
Taylor, CC ;
Kinon, BJ ;
Breier, A .
CLINICAL THERAPEUTICS, 2000, 22 (09) :1085-1096
[19]   Trends in the use of antidepressants in a national sample of commercially insured, pediatric patients, 1998 to 2002 [J].
Delate, T ;
Gelenberg, AJ ;
Simmons, VA ;
Motheral, BR .
PSYCHIATRIC SERVICES, 2004, 55 (04) :387-391
[20]  
Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002